alone is estimated to have an annual global mor tality of approximately 2.7 million people, cause significant morbidity in >200 million people [9] , and is on target to be the third largest cause of global mortality by 2020 [10] .
While the exact mechanism(s) of disease onset are still unknown, environmental exposures are directly linked to the development of lung dis eases. In addition to triggering of allergic asthma by a range of environmental allergens, including grass pollen [11] , birch pollen [12, 13] dust mites [14] or cat allergens [14] , there are many other environ mental factors that can exacerbate existing pul monary conditions; for example, exposure to air pollution in urban areas [15] [16] [17] [18] , diesel exhaust [19] , smoke from heating fires in rural areas [20] , and smoke from indoor cooking fires [21, 22] . Air pollution in urban areas has been shown to have a detrimental effect on the health of individuals with asthma, especially children [23] [24] [25] . Long and shortterm exposures have been shown to induce a range of atopic conditions, including wheezing [26] , eczema and allergies [27] , and even hospitalization [28] , all of which lead to a worse quality of life for many children. In developing countries millions of people are exposed to high levels of air pollution, due to smoke from inef ficient and poorly ventilated solid fuel fires (bio mass or coal) [21, 22, 29] . The smoke from these fires has been shown to have a similar composition to tobacco smoke [30] and cause health problems including COPD [22, 31] , strokes [32] , ophthalmic disorders [33] , TB [34] and cancer [31] .
Application of metabolomics approaches to the study of respiratory diseases
Metabolomics is the global unbiased ana lysis of all the small-molecule metabolites within a biological system, under a given set of conditions. These methods offer the potential for a holistic approach to clinical medicine, as well as improving disease diagnosis and understanding of pathological mechanisms. Respiratory diseases including asthma and chronic obstructive pulmonary disorder are increasing globally, with the latter predicted to become the third leading cause of global mortality by 2020. The root causes for disease onset remain poorly understood and no cures are available. This review presents an overview of metabolomics followed by in-depth discussion of its application to the study of respiratory diseases, including the design of metabolomics experiments, choice of clinical material collected and potentially confounding experimental factors. Particular challenges in the field are presented and placed within the context of the future of the applications of metabolomics approaches to the study of respiratory diseases. Current clinical diagnosis of respiratory dis eases relies on a trained clinician making a deci sion based upon patient medical history and pre sentation of symptoms. A range of quanti tative and semiquantitative tests, including radiologi cal examinations, spirometry [35] , sputum ana lysis [36] and, more recently, exhaled nitric oxide [36, 37] , have been used to improve clinical diag nosis of respiratory diseases. Carbon monoxide testing has been shown to be of utility in assessing the smoking status of patients with COPD [38] . There are also numerous chemical tests that can be used to improve clinical diagnosis of respira tory diseases, which quantify the concentrations of a range of markers [39] . Whilst tests that utilize a single biomarker can provide valuable informa tion for clinical diagnosis, they tend to have rela tively low specificity. In addition, they are often incapable of identifying and diagnosing specific disease subphenotypes [39, 40] . This means that it is often challenging to accurately phenotype patients in terms of the diagnostic subpheno type [39] (e.g., aspirinintolerant asthma [41] ). However, MSbased techniques have been used to measure leukotriene B4 (LTB 4 ), a marker of inflammation [42] , and 8isoprostane, a marker of oxidative stress [43] , in exhaledbreath conden sate [44, 45] . Nonetheless, disease subphenotypes are poorly described by existing diagnostic cri teria and it is expected that approaches employ ing multiple chemical biomarkers will improve the accuracy and specificity of clinical diagnoses [39, 46] . For example, different biomarkers of the same clinical condition are often only weakly, if at all, correlated [47, 48] , indicating that these markers do not provide a comprehensive picture of disease status.
There are a number of challenges that need to be addressed to improve diagnosis and treatment of respiratory diseases: disease subphenotypes are poorly described using existing diagnostic criteria [39] , which means that there is a need for rigorous phenotyping to characterize specific disease states [48] ; many current markers are not specific and only enable the generic diagnosis of the disease (e.g., asthma), which makes it neces sary to identify sets of new biomarkers capable of diagnosing specific disease subphenotypes; and understanding of the disease processes is still poor, particularly at the metabolic level, and especially in terms of the onset of disease and the response to therapeutic intervention. One major unmet need in respiratory medicine is, therefore, to identify biomarkers that reflect specific patho biologies. It is expected that the application of
Introduction to metabolomics
Metabolomics is "the ana lysis of the whole of the metabolome under a given set of conditions" [68] . The exact definition of the metabolome is sub ject to some debate, but generally can be thought of as the complete compliment of all of the lowmolecular weight molecules (<1500 amu) present in the biological compartment in a par ticular physiological state under a given set of environmental conditions (adapted from [69] ). This definition of metabolomics requires that the entire chemical diversity of the metabolome is captured simultaneously; however, this is not possible with currently available technologies [70] . For example, detected metabolite composi tion in a given matrix is dependent upon mul tiple parameters, including extractionsolvent polarity [71] , choice of chromatographic column (e.g., C 18 , ion exchange, hydrophilicinter action LC) [72] and detector (e.g., UV, Raman, mass spectrometer). Accordingly, a single analyti cal approach will only provide a snapshot of the system. The obstacles faced in analyzing the metabolome were well demonstrated in a recent study by Psychogios et al., who used a multi platform approach to examine the human serum metabolome [73] . In order to achieve a coverage of 4229 metabolites, six distinct analytical platforms were required, including highresolution NMR, GC-MS, LC-MS and direct flow injection-MS. While representing one of the most comprehensive studies to date on the human serum metabolome, the identi fied metabolites most likely do not cover the entire potential metabolome, with the Human Metabolome Database containing over 7900 distinct metabolites to date [74, 301] . In addition, it is not feasible to routinely apply six different 
Chronic obstructive pulmonary disorder:
Heterogeneous disease characterized by airflow obstruction associated with chronic bronchitis, bronchiolitis, emphysema or fibrosis.
Cystic fibrosis: Autosomal recessive genetic disorder that causes the body to produce abnormally thick and sticky mucus. The disease particularly affects the lung and digestive system and is characterized by abnormal transport of ions (sodium and chloride) across epithelia, resulting in viscous secretions.
Metabolomics: Analysis of the whole of the metabolome under a given set of conditions.
Metabolome:
Complete compliment of all of the low-molecular weight molecules (<1500 amu) present in the biological compartment in a particular physiological state under a given set of environmental conditions.
Metabolite profiling:
Targeted quantification of a predefined subset of metabolite components of the metabolome that usually are of related chemical structure and/or biological activity.
future science group analytical platforms to every sample, which would be both expensive and time consuming.
Partially as a result of the difficulty associated with capturing the composition of the metabo lome and the challenges posed by working with highly dimensional datasets, different levels of metabolic ana lysis have been used. These approaches can largely be split into two catego ries: metabolomics [66, 75] and metabolite profiling [64, 65, 76] , although the use of these terms differs greatly in the literature. For the purposes of this review, we will employ the following defi nitions: metabolomics experiments are defined as the "global, unbiased ana lysis of the metabolite composition of the biological compartment in a specific physiological state under given environmental conditions" [77] ; metabolite profiling is defined as the "targeted quantification of a predefined subset of metabolite components of the metabolome that usually are of related chemical structure and/or biological activity" [77] ; and metabolite finger printing approaches are "rapid high-throughput techniques that group data according to shared biochemical characteristics, distinguishing these features from background variation without identifying individual metabolite annotations" [78] . In a metaboliteprofiling experiment, authentic ana lytical standards for each metabolite being ana lyzed are employed, enabling exact quantitation [79] . This is not feasible in global metabolomics due to the large number of variables, the exact metabolite identity of which is often unknown [80] [81] [82] . Of course, in a metabolite profiling experiment only changes in the focused set of metabolites will be observed, whereas the global nature of metabolomics experiments enables novel areas of metabolism to be identified [83, 84] .
Numerous analytical techniques can be used in metabolomics ana lysis; however, they can largely be split into two categories: NMR [54, 85] and MS [86, 87] (although applications with capillary electrophoresis [88] and other spectral approaches [UV, IR and Raman] are employed for selected applications). While it is generally less sensitive than MS [89] , NMR requires minimal sample preparation prior to ana lysis and offers relatively short analytical run times [89] , making it a robust highthroughput technology capable of rapidly analyzing large numbers of samples. NMR techniques are also non destructive, allowing intact metabolites to be analyzed [90] , which can simplify metabo lite identification and enables the retention of samples for repeat or further indepth followup analyses. These advantages, as well as relative ease of data interpretation, may explain why NMR techniques have been more widely utilized in the study of respiratory diseases [3, 64, 65, 67, [91] [92] [93] relative to MS [66, 94] .
There are multiple approaches to applying MS; however, they can be approximately catego rized into two principle types: chromatography coupled MS and direct or flowinfusion MS. Chromatographycoupled techniques attempt to simultaneously detect and quantify metabolite peaks, following separation of the sample on a chromatographic column. Chromatographic separation can be achieved in either the gas or liquid phase, depending upon the target ana lytes. GC-MS techniques are routinely capa ble of resolving hundreds of metabolite peaks, with metabolite identifications commonly per formed by matching electron impact fragmen tation spectra and retention indices to estab lished libraries [95] . 2D GC (GC × GC-MS) approaches have also been used in metabolomics [96] [97] [98] [99] , and because these techniques employ two orthogonal GC columns, an increased number of metabolites can be separated in a single run [100] . GC-MS techniques are limited to the ana lysis of volatile, thermally stable and relatively nonpolar compounds. Compound volatility can be increased using derivatization; how ever, this step is laborious and can potentially increase annotation complexity [82] . LC-MS sys tems are capable of analyzing a wider range of chemical species, including polar and nonvola tile compounds, over a greater mass range than GC-MS approaches and do not require sample derivatization [101] . A significant obstacle in LC-MS approaches is the lack of established spectral libraries, but efforts such as the METLIN [102] and FiehnLib [103] databases represent signifi cant advances. Interested readers are directed to a number recent reviews for more information on the theory and application of MS [104] [105] [106] .
Rather than performing timeconsuming sample separation prior to ana lysis, it is also pos sible to utilize directinfusion MS techniques, in which metabolites are represented simply as a mass variable (m/z) [75, 107] . Directinfusion metabolite fingerprints can be generated in two ways: first, by dissolving the sample in an appro priate solvent and injecting it directly into the ionization chamber (directinjection MS); or sec ond, the sample can be infused into the ioniza tion chamber in a plug of solvent (flow infusion electrospray ionizationMS [FIEMS] ). Those methods that do not separate sample components prior to ana lysis are particularly susceptible to future science group ion suppression, which is caused by changes in the ionizationspray droplet due to the pres ence of high abundances of less or nonvolatile compounds [107] . The detailed comparison of different metabolomics technologies falls out side the scope of this review, although numer ous review articles have addressed these topics specifically [85, [107] [108] [109] [110] .
Choice of clinical material to be analyzed: the importance of matrix selection One of the primary considerations in the design of a clinical metabolomics experiment is the choice of patient material. There are several biofluids that can be collected, including urine, plasma, serum, saliva, exhaledbreath condensate (EBC), induced sputum supernatants, bronchial wash and bronchoalveolar lavage fluid (BALF). The decision regarding which biofluid to sample is affected by a number of considerations [111] , with each matrix possessing a unique combi nation of strengths and weaknesses (Table 1) . Urine, plasma and serum are useful due to ease of collection and minimally invasive nature [39, 109] . The standardized nature of collection protocols for these biofluids renders them particularly suit able for use in large multicenter studies [109] . Due to extensive analyses in multiple studies, the pro tein, lipid and metabolite composition of these matrices is relatively well documented. Urine is also attractive due to its low levels of proteins and cellular material [109] , and normalization of total metabolite content using creatinine is well described [110, [112] [113] [114] . Urine, plasma and serum are integrated bio fluids. This offers the simulta neous advantage of reflecting both localized and systemic changes; however, it can be difficult to identify the origins of the observed metabolic changes. Plasma and serum also possess a num ber of analytical challenges: high protein concen trations means samples require deproteinization prior to ana lysis [109] ; it is preferable to avoid the addition of anticoagulating agents such as hepa rin, citrate and EDTA because they can affect the metabolite composition of samples [115] ; and there can be significant matrix effects associated with ana lysis [109] . It is also important to note Table 1 . Advantages and disadvantages of the use of different biofluids to characterize respiratory diseases.
Biofluid

Advantages Disadvantages
Urine Collection easy and noninvasive Low protein and cellular material [52, 64] Integrative biofluid
Normalization for dilution (creatinine)
Monitors whole body metabolism Not directly linked to lung tissue Presence of high salt levels Plasma/serum Integrative biofluid [109] Easy to collect
Well-described composition
Requires deproteinization prior to ana lysis [109] Distant from tissue, biases towards systemic changes Can contain collection artefacts Induced sputum Present in lower respiratory tract [225] Standardized collection and standard operating procedures Susceptible to confounding factors [123] Limited reports in literature to guide method development Exhaled-breath condensate
Noninvasive collection
Suitable for analyzing volatile and nonvolatile compounds [89] Contains mainly polar metabolites that while working with plasma and serum is similar, the metabolite composition of these two biofluids is distinct [116] . In addition, the gen eration of plasma can result in the formation of artefacts and commensurate shifts in metabo lite levels that are solely a result of the sample collection process [117] . EBC and saliva are utilized in metabolomics studies due to the ease and noninvasive nature of collection [2, 42, 44, 89, 92, 93, 118, 119] . However, because they have yet to be widely employed, protocols for their collection are not widely standardized, leading to potentially high variability between laboratories. EBC is dilute and often requires concentration prior to ana lysis, which can lead to increased intersample variability. It has been suggested that EBC can be normalized for solute concentration using the sum of the sodium and potassium ions [120] . Saliva has been normalized using amylase concentrations [121] ; however, saliva is susceptible to a range of confounding factors that affect the composition of the metabolome (a confounding factor is an internal or external source of metabolic variability that can obfus cate the detection of metabolic changes resulting from the factor being studied). Saliva is especially vulnerable to the effects of diet [122] and smoking [123] , but changes resulting from factors includ ing gender [123] and sampling time [67] have also been reported. A small number of metabolomics studies have analyzed BALF [124, 125] ; however, the highly invasive and expensive nature of sam ple collection renders it a lessattractive biofluid with which to work. Bronchoscopy can only be performed by welltrained specialists on a limited number of patients [126] and is, therefore, gener ally not suitable for the collection of temporally associated longitudinal studies. Variability in the volume of saline recovered during collection is a concern; however, normalizing the data using the ratio of instilled versus recovered volume has been shown to slightly reduce variability [127] . BALF samples are also dilute and require concentra are also dilute and require concentra tion prior to ana lysis, which can introduce fur ther variability. Whilst some metabolite profiling work has been performed on sputum [128] , global metabolomics techniques have yet to be applied, which may be due to a number of challenges faced in working with this matrix (Table 1) .
Following the choice of clinical material, it is important to design a sampling strategy that will minimize variability and remove sampling bias. A number of factors present in a daily routine significantly affect the metabolome composi tion (Table 2) , including gender [123] , smoking [123] , sampling time [67] , diet [122] , environment [15, 16] , age [129, 130] , exercise [131, 132] and associated comorbidities. Some reported studies chose not to control these confounding factors, under the rationale that "the metabolites of interest would be altered sufficiently between disease and nondisease groups that such intrapersonal variability would be superseded" [64, 65] . Saude et al. were able to clas were able to clas sify stable asthmatic patients with an accuracy of 94%, yet only matched the age and gender com position. Numerous strategies have been used to correct for intra and interpersonal variability:
Fasting prior to blood or urine collection can reduce the impact of dietrelated effects [104, 133, 134] ;
Food frequency questionnaires have been widely used in nutrition studies, and allow compositional changes to be linked to changes in food intake [135] ; however, food frequency questionnaire compliance has been shown to be a problem [136] ;
Standardization of urine collection protocols is important with different strategies required depending upon the study aim (e.g., first evac uation of the day, collection in the clinic, col lection in the home, collection and combination of multiple samples). Higher in men [123] Gender Formate Higher in men [123] Gender Glycine Higher in men [123] Gender Lactate Higher in men [123] Gender Methanol Higher in men [123] Gender Propionate Higher in men [123] Gender Propylene glycol Higher in men [123] Gender Pyruvate Higher in men [123] Gender Succinate Higher in men [123] Gender Taurine Higher in men [123] Gender Alanine Lower at night [67] Sampling time Choline
Lower at night [67] Sampling time Methanol
Higher at night [67] Sampling time N-acetyl groups Higher at night [67] Sampling time Propionate
Lower at night [67] Sampling time Trimethyamine oxide Lower at night [67] Sampling time 91, 93, 138] and cystic fibrosis [66, 92, 125, 137] with a high degree of accu racy. No known studies have, to date, investi gated sarcoidosis or other respiratory diseases.
The high classification accuracy of these mod els, generated from sample material that was collected noninvasively (e.g., urine and EBC) suggests that metabolomics approaches can play a central role in diagnosing/characterizing respiratory diseases. Metabolomics approaches have also identified the individual candidate metabolites that are responsible for discrimi nating respiratory disease patients and healthy controls within these experiments (Tables 3-6 ). These lists of metabolites render it possible to tentatively identify distinct areas of metabolism and the pathways that characterize the individ ual disease metabolic phenotypes. We present these studies on a diseasespecific basis below.
Asthma NMR metabolite profiling techniques were used to classify both stable and exacerbated asthma compared with healthy controls, with an accu racy of 94% [65] . Partial least squares-discrimi nant ana lysis (PLSDA) modeling of these data identified 23 metabolites present at different abundances in asthma patients compared with 1-methylhistamine Urine [64, 65] NMR [64, 65] Increased NP 1-methylnicotinamide Urine [65] NMR [65] Increased NP 2-hydroxyisobutyrate Urine [64, 65] NMR [64, 65] Increased NP 2-oxoglutarate Urine [64, 65] NMR [64, 65] Decreased NP 3-OH-3-methylglutarate Urine [64, 65] NMR [64, 65] Decreased NP Acetone
Urine [65] NMR [65] Increased NP Alanine Urine [65] and EBC [93] NMR [65, 93] Increased Decreased Carnitine Urine [64, 65] NMR [64, 65] NP NP Creatine Urine [64, 65] NMR [64, 65] Increased NP Dimethylamine Urine [64, 65] NMR [64, 65] Increased NP Formate Urine [65] and EBC [93] NMR [65, 93] Increased Increased Glucose Urine [64, 65] NMR [64, 65] Increased NP Glycolate Urine [64, 65] NMR [64, 65] Decreased NP Hippurate
Urine [65] NMR [65] Decreased NP Lactate Urine [65] and EBC [93] NMR [65, 93] Increased Decreased 1-methylimidazolacetic acid Urine [94, 150] UPLC-Q-tof [94] Decreased NP Methylamine Urine [64, 65] NMR [64, 65] Decreased NP O-acetylcarnitine Urine [65] NMR [65] Decreased NP Phenylacetylglycine Urine [64, 65] NMR [64, 65] Increased NP Phenylalanine Urine [64, 65] and EBC [93] NMR [64, 65, 93] Increased Increased Propionate EBC [93] NMR [93] NP Decreased Pyruvate EBC [93] NMR [93] NP Increased Succinate Urine [64, 65] and EBC [93] NMR [64, 65, 93] Increased Increased Taurine
Urine [65] NMR [65] Increased NP Threonine Urine [65] and EBC [93] NMR [65, 93] Decreased Decreased Trans-aconitate Urine [65] NMR [65] Increased NP Trigonelline
Urine [65] NMR [65] Increased NP Trimethylamine Urine [64] and EBC [93] NMR [65, 93] Increased Increased Trimethylamine N-oxide Urine [65] NMR [65] Decreased NP Tryptophan
Urine [65] NMR [65] Increased NP Urocanic acid Urine [94, 155] UPLC-Q-tof [94] (Tables 3 & 4) . Mattarucchi et al. classified a range of atopic asthma pheno types using orthogonal projections to latent structures discriminant ana lysis (OPLSDA) models gener ated from nontargeted LC-MS metabolomics data generated from urine samples [94] . Three models were generated -the first model clas sified asthmatics against healthy controls with an accuracy of 98%; the second model classi fied medicated versus nonmedicated asthmatics with an accuracy of 96%; and the third model classified patients with wellcontrolled asthma from poorly controlled asthma with an accuracy of 100%. Deeper investigation of these data revealed three metabolites that were excreted at lower levels in asthma patients: urocanic acid, In individuals with asthma who have recently suffered an exacerbation, five metabolites act ing in the TCA cycle, succinate, fumarate, oxaloacetate, cisaconitate and 2oxogluta rate have all been reported as being present at higher abundances in urine compared with controls (Figure 1 ) [65] . This increase in the abundance of TCA cycle intermediates suggests an up regulation in TCAcycle metabolism as the result of a greater effort to breathe during exacerbation and/or hypoxic stress due to poor oxygenation as a result of exacerbation. Similar shifts in TCAcycle metabolism have also been reported during exercise [139, 140] , supporting the hypothesis that increased abundances of these metabolites during exacerbation is a result of the effort to breath and hypoxic stress. Higher levels of lactate were also reported during exac erbation (Table 4) , further supporting the idea that patients are undergoing hypoxic stress, because increased levels of this metabolite have been reported during periods of anaerobic exercise [141] . However, during these periods of exercise, increases in the abundance of lactate have been reported as occurring in conjunction with a decrease in the abundance of citrate [140] , which has not been observed in individuals with asthma. Nicholson et al. hypothesized that this increase in the abundance of lactate would lead to lactic acidosis, which would in turn cause renal tubular acidosis leading to lower levels of glycine and hippurate in urine [142] , as both of these compounds have been described as biomarkers of reversible renal malfunction [143] . Neither of these metabolites has been reported as being reduced in abundance in urine after future science group exacerbation, conversely, hippurate is reported as increasing in abundance (Table 4 ). This sug gests that if hypoxic stress is occurring, then it is not at sufficient levels to cause renal mal function. Hippurate is reported at lower con centrations in the urine of stable asthmatics, in conjunction with increased levels of lactate and some intermediates of the TCA cycle (e.g., suc cinate). These data might potentially suggest that individuals with asthma may permanently suffer from some degree of hypoxic stress lead ing to lowlevel renal malfunction; however, this is highly speculative and there are no reports in the literature to support this theory. 1methylhistamine is a major downstream metabolite of histamine, a significant pro inflammatory agent [144, 145] and mediator of inflammation [146, 147] , as well as an impor as well as an impor tant component of allergic metabolism. 1methyl histamine is produced via the meth ylation of histamine by histamine methyltrans ferase [148, 149] . 1methylimidazolacetic acid is a downstream product of the histamine methy lation pathway (Figure 2) , with both 1meth ylhistamine and 1mehtylimidazolacetic acid occurring at modified abundances in asthma patients (Table 3) . 1methylhistamine is reported at higher abundances in asthma patients [65] , with lower levels of 1methylimidazolacetic observed in the urine of individuals with asthma [94, 150] . In experiments using 14 Clabeled histamine, methylation was the primary route of histamine metabolism in humans [123, 151] , suggesting that 1methylhistamine and 1methylimidazolacetic acid are appropriate urinary markers of hista mine metabolism [152] and potential biomark ers for the diagnosis of pathological inflam mation. Histamine release has been reported 1-methylnicotinamide PHAECC [66] UHPLC-MS [66] Increased 2-propanol EBC [92] NMR [92] Discriminate CF and HC Acetate EBC [92] NMR [92] Discriminate CF and HC Acetone EBC [92] NMR [92] Discriminate CF and HC Adenosine PHAECC [66] UHPLC-MS [66] Decreased Anthranilate PHAECC [66] UHPLC-MS [66] Increased Cytidine PHAECC [66] UHPLC-MS [66] Decreased Formate EBC [92] NMR [92] Discriminate CF and HC Fructose PHAECC [66] UHPLC-MS [66] Decreased Fructose-6-phosphate PHAECC [66] UHPLC-MS [66] Decreased Glucose PHAECC [66] UHPLC-MS [66] Decreased Glucose-6-phosphate PHAECC [66] UHPLC-MS [66] Decreased Glutamate EBC [92] NMR [92] Discriminate CF and HC Glutamine EBC [92] NMR [92] Discriminate CF and HC Glutathione (oxidized GSSG)
PHAECC [66] UHPLC-MS [66] Decreased Glutathione (reduced GSH)
PHAECC [66] UHPLC-MS [66] Decreased Glycerophosphorylcholine PHAECC [66] UHPLC-MS [66] Decreased Guanosine PHAECC [66] UHPLC-MS [66] Decreased Hypoxanthine PHAECC [66] UHPLC-MS [66] Decreased Inosine PHAECC [66] UHPLC-MS [66] Decreased Kynurenine PHAECC [66] UHPLC-MS [66] Increased Lactate PHAECC [66] and EBC [92] UHPLC-MS [66] and NMR [92] Decreased Malate PHAECC [66] UHPLC-MS [66] Decreased Mannose-6-phosphate PHAECC [66] UHPLC-MS [66] Decreased Nicotinamide PHAECC [66] UHPLC-MS [66] Decreased Opthalmate PHAECC [66] UHPLC-MS [66] Decreased Propionate EBC [92] NMR [92] Discriminate CF and HC Ribulose-5-phosphate PHAECC [66] UHPLC-MS [66] Decreased S-lactoylglutathione PHAECC [66] UHPLC-MS [66] Decreased Sorbitol PHAECC [66] UHPLC-MS [66] Decreased †
'Increased' indicates higher levels in cystic fibrosis patients and 'decreased' indicates lower levels in cystic fibrosis patients. CF: Cystic fibrosis, EBC: Exhaled-breath condensate; HC: Healthy controls; PHAECC: Primary human airway epithelial cell cultures.
future science group during mastcell activation in individuals with allergic asthma [153, 154] . This might suggest that the changes in the abundance of 1methylhis tamine, 1methylimidazolacetic and urocanic acid observed are also linked to mastcell acti vation. The change in abundance of these two metabolites along with decreased levels of uro canic acid in individuals with asthma [94, 155] is consistent with a reduction in the metabolism of free histamine [150] . Kerr [150] suggested that the methylation step is the most likely location for the blockage in histamine metabolism; however, the reported increase in the levels of 1methyl histamine (Table 3) in asthmatics makes this unlikely because if the blockage was upstream of this metabolite, it would not accumulate.
COPD Analysis of serum samples using NMR has been successfully used to classify severe COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage III [156] ) and very severe COPD (GOLD stage IV) patients with an accuracy of 82% [91] , where decreased levels of branchedchain amino acids (BCAA) and their associated metabolites are responsible for the discrimination of COPD patients and healthy controls [91] . LC-MS ana lysis of plasma samples successfully classified emphysematous COPD and nonemphysematous COPD patients with an accuracy of 64% using hierarchical cluster ing [138] . This classification accuracy is relatively low; however, when using linear discriminant ana lysis on a subset of biomarkers classification accuracy was improved. When using the seven optimal biomarkers, classification accuracy was improved to 97% [138] , although the biomarkers were not identified.
The most significant area of metabolism identified as discriminating COPD patients from healthy controls is the metabolism of BCAA (Table 5) [91, 157] , with valine, isoleu cine and their degradation product 3hydrox yisobutyrate reported at lower abundances in Figure 1 . Section of the TCA cycle. Highlighted metabolites have been reported to increase in abundance shortly after asthma exacerbation. Adapted with permission from [309] .
future science group patients suffering from COPD (Figure 3 ). This modification of BCAA metabolism might be the result of cachexia (a wasting syndrome char acterized by muscle atrophy, fatigue, weakness and significant weight loss) in COPD patients. During extended periods of fasting the prote olysis of skeletal muscle and the transamination of BCAA by branchedchain aminotransferase (BCKHD) is an important metabolic response providing a resource for gluconeogenesis [91] . Increased levels of gluconeogenesis that are not suppressed by glucose have been reported in patients suffering from cachexic weight loss [158] . This hypothesis is consistent with the results reported in Ubhi et al., which showed that the reduction in BCAA's correlated with the patient body mass index [91] . Increased levels of BCAA catabolism have also been reported in urine samples collected after exercise [140] , where the increase in BCAA catabolism is thought to be the result of proteolysis in skeletal muscle and the visceral region [159] . This might be the result of increased gluconeogenesis due to increased demand for energy during exercise. If accurate, these findings would support the hypothesis that the lower levels of BCAAs in COPD patients are the result of proteolysis, potentially due to wasting.
Cystic fibrosis
The ana lysis of NMR spectra generated from EBC has been used to classify patients with cystic fibrosis relative to healthy controls with a classification accuracy of 96%. Validation of this model showed that it had a sensitivity of 91% and a specificity of 96% [92] . A second model was gen erated from these data, classifying stable versus unstable cystic fibrosis patients with an accuracy of 95%. Validation showed that this model had a sensitivity of 86% and a specificity of 94% (the metabolites responsible for the discrimination in both of these models are provided in Table 6 ) [92] . Preliminary metabolomics ana lysis has been per formed looking at BALF collected from pediatric cystic fibrosis patients, which could be classified into high and low inflammation groups [125] . An OPLSDA model of NMR spectra was generated that was able to discriminate the two groups of patients. This model had an R 2 Y of 0.96 (i.e., the model explained 96% of the variation observed within the data) and a Q 2 of 0.80, indicating that the model had good predictive power.
As with asthma and COPD, the metabolomics studies looking at cystic fibrosis performed to date have successfully identified numerous metabo lites and areas of metabolism that characterize the disease state (Table 6) . Sorbitol, fructose, glucose, Adapted with permission from [310] .
future science group mannose6phosphate, fructose6phosphate, ribulose5phosphate and glucose6phosphate have all been reported as occurring at lower abun dances in primary human airway epithelial cell cultures [66] . These metabolites act in at least one of three linked metabolic pathways (glycolysis/ gluconeogenesis, pentose phosphate pathway and fructose/mannose metabolism) that are involved in the metabolism of glucose (Figure 4) . Glucose metabolism plays a central role in normal cellular Adapted with permission from [311] .
future science group function, providing both energy [66] and biosyn thetic precursors for the synthesis of a range of biomolecules including nucleotides and fatty acids. It is also interesting to note that suppres sion of glucose metabolism, as indicated by the reduced abundances of these metabolites, could be responsible for reduced cellular abundances of sorbitol (Figure 4) . Sorbitol is an important cellular osmolyte and plays a crucial role in main taining cellular volume and fluid balance [160] . Sorbitol has also been described as promoting the proper maturation of CFTR protein [161] , which is an ATPgated anionselective channel that transports chloride ions across the epithelial cell membrane [162] . The transport of chloride ions plays a crucial role in maintaining airway surface liquid volume. Accelerated Na + absorption and defective Cl secretion in airway epithelial cells is the underlying cause of the pathogenic thicken ing of airway mucus observed in cystic fibrosis patients [163] .
The abundances of five purines and purine metabolites (adenosine, guanosine, inosine, hypo xanthine and adenine) have also been reported to be lower in cystic fibrosis patients (Table 6 ), suggesting that these patients exhibit lower levels of purine synthesis relative to healthy controls ( Figure 5 ). This is biologically important because purines have been shown to act as signaling mol ecules [164, 165] . Adenosine is especially relevant to cystic fibrosis, because it has been reported to play a role in controlling the viscosity of airway mucus by regulating airway surface liquid volume through activation of CFTR receptors [166, 167] . In studies of rat lung tissue, the addition of adenos ine directly increased chloride ion flux through CFTR ion channels [168] . Three metabolites relating to glutathione -reduced glutathione, oxidized glutathione and Slactoylglutathione -have been reported at lower concentrations in primary human airway epithelial cell cultures (Table 6) . A number of metabolites related to glutathione, including Snitrosoglutathione and Snitrosylating compounds act to promote CFTR cellsurface expression and channel activation in cystic fibrosis epithelial cells [169, 170] . As well as these global metabolomics efforts, metabolite profiling of oxylipins has also been used to study cystic fibrosis [171, 172] .
Challenges in applying metabolomics to the study of respiratory diseases
The application of metabolomics techniques to the study of respiratory diseases faces a number of significant challenges, some of which are com mon to all metabolomics experiments and some of which are more specific to clinical studies. The most significant of these are discussed below.
Biobanks
The generation of biobanks is part of the grow ing trend towards the use of largescale biology (such as 'omics' and systems biology) to address questions in clinical science. The term biobank generally refers to repositories of biological mate rial that are relevant to the study of disease [173] . Biobanks are likely to play an integral part in the future of biomedicine because they can supply sufficient numbers of samples to power large scale systemsbased studies. Biobanks will also provide the opportunity to study the etio logy of diseases from large populations in a longitudi nal fashion, greatly increasing the sensitivity for detecting shifts relating to the onset of disease. For example, the 'LifeGene' biobank aims to col lect samples from 500,000 patients, which rep resents approximately 5% of the Swedish popu lation, thereby enabling diseases to be studied at the population level [174] . However, a number of important ethical issues with using biobanks have been raised [175] [176] [177] . There are also a range of analytical challenges faced in using metabo lomics techniques to analyze biobank samples. One of the foremost issues is the reproducibility of sample collection strategy employed in the studies, making the development of a standard ized collection protocol important [178] . A second major obstacle is the effect of longterm storage on the sample metabolite composition. Even samples stored at 80°C have been demonstrated to exhibit metabolite loss during storage [71, 179] , with the rate of loss dependent upon the matrix and analyte. For these vast libraries of samples that are being collected in biobanks to be useful in the metabolomics study of clinical diseases, it is necessary to develop and implement a range of standard operating procedures for sample col lection [178] and prestorage processing [180] . It is also important to assess the effects of different storage strategies on the metabolite composi tions of samples to identify the strategy that best preserves the true metabolic phenotype of the sample, and to identify the limits of viable stor age so that time and resources are not wasted on analyzing poorquality samples. Towards this end, reliable degradation markers should be iden tified to monitor sample integrity. Another issue involves sample ownership, with potential con flicts between researchers who deposit samples in biobanks and the clinical entities that maintain the biobanks. Interested readers are directed to the Biobanking and Biomolecular Resources Research Infrastructure Initiative [302] . It has also been suggested that the interpretation of results generated from biobank samples may be prob lematic. This is due to the varied nature of respi ratory diseases, which exhibit large deviations in pathological phenotype. These differences will make it potentially difficult to link experimen tal results to clinical aspects of the disease [173] -further illustrating the need for rigorous and standardized clinical phenotyping of patients.
future science group
Experimental design
The high intra and interindividual variabil ity need to be addressed in clinical studies [181] [182] [183] . Strategies for controlling confounding factors (e.g., diet [122] and smoking [123] ) have been described, including matching the age Adapted with permission from [315] .
future science group and gender composition of sample groups [65] , smoking history of patients [91] , and patient fasting prior to sample collection [104, 133, 134, 184] . However, these approaches only reduce the vari ability introduced by these confounding factors and do not completely remove it. These strate gies also introduce problems related to patient conformity (i.e., patient compliance with study protocols regarding dietary and behav ioral restrictions). It would be advantageous to develop analytical strategies to account for this variability; for example, metabolites that are modified in abundance as the result of disease should correlate across all patients with the dis eased state, and metabolite abundances that are modified as the result of confounding factors should be excluded. Metabolomics experiments also suffer from problems of poor laboratorytolaboratory repro ducibility, this is especially true for nontargeted MSbased techniques. To facilitate collaborative research between multiple laboratories, strategies to reduce this variability should be implemented. Initially, mRNA microarray experiments suf fered from similar limitations, although studies have now shown that interlaboratory variability can be reduced via use of common platforms and procedures [185, 186] . It has also been shown (for microarray ana lysis) that data normalization is a vital component in reducing variability [185] . The ana lysis of standard reference materials is crucial in reducing interlaboratory variability [187] . The inclusion of reference materials also enables comparison of instrumental accuracy/ precision between sample batches, experiments and analytical platforms [187] . One strategy to address this variability is to normalize metabo lite abundance by total metabolite composition, which can remove effects of sample dilution in biofluids. Methods for normalizing for sample dilution are well described for saliva using amy lase abundance [121] , and using creatinine in urine [110, [112] [113] [114] . It is especially important for urine because its concentration can vary widely [114] ; however, it is less of an issue in plasma and serum as solute concentration is tightly control led [114] . For NMR spectroscopy it is possible to normalize data for total metabolite content by reference to the total spectral area of each sample [119] . More detailed descriptions of strat More detailed descriptions of strat egies for the normalization of metabolite con centration for total metabolite content [114, 188] , and general discussions of metabolomics and metabolomics workflows [77, 109, 189] , are widely available. While a separate subject in and of itself, the field of design of experiments (DOE) is extremely important, but is unfortunately rarely discussed in either clinical or analytical papers. DOE selects a diverse and representa tive set of experiments in which all factors are independent of each other despite being varied simultaneously. The result is a causal predic tive model showing the importance of all fac tors and their interactions [303] . Increased effort placed on appropriate DOE will enable the use of decreased sample numbers while maintaining experimental power and will be a useful tool in clinical metabolomics [190] .
Data ana lysis
Data ana lysis is a critical part of all metabolo mics experiments, regardless of the biological system or analytical instrument in question, and presents a major challenge to the development and application of metabolomics techniques. The statistical ana lysis of metabolomics data is challenging for multiple reasons, with detailed discussion of these problems being outside the scope of this review. A number of articles have dealt with these problems in detail [191] [192] [193] [194] and only a few of these issues will be highlighted here. Metabolomics experiments, along with most largescale biology studies in general, have few degrees of freedom, consisting of low sam ple number combined with highdimensionality datasets. It is accordingly challenging to derive meaningful biological knowledge via visual ana lysis of the dataset [195] . Identifying the approp riate statistical approaches is therefore one of the foremost challenges in data ana lysis. Univariate statistics, such as ana lysis of variance (ANOVA) and Student's ttest, identify variables as being significant at a given probability (i.e., a = 0.05, which means that there is a 5% chance that any given variable is identified as being significant by chance, a socalled falsepositive or type I error.) Within large metabolomics datasets containing thousands of variables [189, 196, 197] , there are potentially hundreds of falsepositives, which can be referred to as the falsediscovery rate (FDR) [198, 199] . Many studies within the 'omics' paradigm employ various approaches to data ana lysis in addressing the FDR issue, including Tukey's honestly significant differ ence [200] , the Bonferroni correction [201] , Holm Bonferroni [202] , the Šidák correction [203, 204] and Benjamini and Hochberg [198] . The drawback to many of these approaches for correcting for multiple hypothesis testing relates to the issue of false negatives (type II errors). There is a strong future science group likelihood that application of an FDRbased correction will result in the generation of false negatives, which is particularly problematic in a hypothesisgenerating experiment. Accordingly, any statistical treatment of the data will have to balance type I and II errors appropriately to address the aim of the study.
Another approach that has been particularly employed in the metabolomics community is the use of multivariate statistical ana lysis. There are numerous multivariate statistical techniques that can be applied to metabolomics data, including unsupervised techniques (e.g., principal com ponent ana lysis [51, 205] ), supervised techniques (e.g., PLSDA [143, 205] , OPLSDA [206, 207] , bi directional OPLS [O2PLS] [208, 209] ) and more specialized approaches such as ensemble classi fiers (e.g., random forest [210] ). For any multi variate ana lysis, it is important to report the appropriate model statistics. At the minimum, the R 2 and Q 2 values should be provided for principal component ana lysis, PLS, OPLSDA and O2PLS models, and eigen values for linear discriminant ana lysis. In addition, the number of components, and CVANOVA pvalues, should be provided where appropriate, such as in dis criminant ana lysis. The values of R 2 and Q 2 are commonly utilized model statistics to evaluate a multivariate model. The R 2 represents the per centage of variation within a dataset that can be explained by the model, which is often referred to as a measure of fit. The Q 2 is the percentage variation of the response predicted by the model according to the cross validation, in other words, how accurately the model can predict new data. Unfortunately, many papers omit these values, making it impossible for the reader to assess the quality of the model. Visual inspection of the model does not give evidence of significant separation, especially for supervised methods.
To improve the reporting of results in metabo lomics experiments it would be advantageous to develop a set of 'minimum reporting standards' for metabolomics data. Ideally, these standards would apply to both the analytical method ology as well as the statistical analyses. Goodacre et al. proposed a set of reporting standards aimed at addressing two main issues: formalize a 'report ing' scheme to prevent confusion over the use of termin ology; and define a set of 'minimum reporting standards' for all stages of ana lysis from data preprocessing to validation of initial hypothesis [195] . These reporting standards repre sent a starting point; however, they are unfortu nately not yet widely adhered to in the scientific literature. The development and implementa tion of datareporting standards to enable the exchange of information is an important goal in metabolomics [184] . The Metabolomics Society has initiated the metabolomics standards ini tiative [304] . These reporting standards outline the minimum information content that should be reported for a metabolomics study, includ ing clear and accurate description of the design and implementation of the study, the subjects involved, biological material sampled and the data collected. This standard ization will increase the accessibility of the information and enable the maximum amount of knowledge to be extracted from a dataset [211] .
Data interpretation A significant bottleneck in an 'omics' experiment is interpretation of the acquired data. It is useful to map the metabolites that describe respiratory diseases on to metabolic pathways to identify both areas of metabolism and specifi c metabolic path metabolism and specific metabolic path ways to develop an improved understanding of the underlying biological perturbation [212] . One of the most powerful tools is the Kyoto Encyclopedia of Genes and Genomes (KEGG) [213, 305] ; how ever, there are others, including WikiPathways [306] , Ingenuity Pathway Analysis, MetaCyc [307] and the Human Metabolome Database [214, 301] . Metabolomics data can be mapped onto KEGG pathways either manually or using the KegArray tool [215] , which is a Javabased application that enables metabolomics data to be considered in isolation or in conjunction with both transcript omics and proteomics data. A relatively new func tion in the KEGG suite is the DISEASE utility, which highlights known metabolic pathways in a range of diseases including asthma (H00079 [308] ). This functionality could play a useful role in interpretation of metabolomics data generated for asthma; however, a closer look at the asthma pathway reveals that there is a significant need for expansion of the mechanistic information to be of utility in data interpretation [127] .
Future perspective
The use of metabolomics approaches in the study of respiratory diseases is still in its infancy and lags behind applications in other diseases. To date both NMR [3, 64, 65, 67, [91] [92] [93] and MSbased [66, 94] 91, 93, 138] and cystic fibrosis [66, 92, 125] in biofluids including urine [3, 64, 65, 94] , EBC [2, 92, 93] , serum [91] , plasma [138] , BALF [125] future science group and sputum supernatants [128] . These studies have demonstrated the power of metabolomics techniques to classify and potentially diagnose patients suffering from multiple respiratory dis eases. In particular, metabol omics approaches have the potential to diagnose respiratory diseases with a higher degree of accuracy than traditional diagnostic methods [2] . Metabolomics approaches have identified several areas of metabolism and metabolic pathways that describe the metabolic phenotype of respiratory diseases. The TCA cycle and histamine metabolism can character ize asthma, with COPD charac terized by BCAA catabolism and cystic fibrosis by glucose, purine and glutathione metabolism. Examining the metabolites that are remodeled in each of these respiratory diseases, it can be seen that whilst some metabolites are remodeled in multiple respiratory diseases compared with controls, the metabolic phenotype of each of the three dis eases is unique. It is also interesting to note that the metabolic phenotype of an asthma exacerba tion is unique to that of stable asthma [65] , rather than it being a simple worsening of the underly ing asthma pheno type. This is also true for the comparison of the metabolic phenotype of stable and unstable cystic fibrosis, with unstable cystic fibrosis possessing a unique phenotype rather than being a worsening of the stable phenotype. Finally, in the context of studies in asthmatics, the influence of treatments, and in particular the widely used glucocorticosteriods, must be determined in future studies.
The use of metabolomics to study respira tory diseases has produced some promising results and its future applications can largely be split into two areas. The first is to identify and describe the shifts in metabolite composition and metabolism associated with different respiratory diseases. Initial efforts in applying metabolomics approaches should focus on gathering as much information as possible to provide an overview of diseasespecific biochemistry. This should be done using both global metabolomics approaches and targeted metabolicprofiling techniques, because global metabolomics methods often lack the sensitivity of metabolicprofiling meth ods. Accordingly, in order to examine the com plete underlying metabolic picture, there is a need for targeted metabolite profiling methods to be performed in parallel to detect lowabun dance compounds (e.g., eicosanoids and other oxylipins) [216] . Targetedprofiling methods have identified numerous lipid mediators that would not otherwise be detected using global, nontargetedmetabolomics methods [79] . These mediators play vital roles in the pathology of a range of respiratory diseases including asthma [25, 79, 217] , COPD [218, 219] and cystic fibrosis [219] [220] [221] . Once sufficient information has been gathered to accurately describe respiratory dis eases, it will be necessary to develop targeted methods that are both quantitative and high throughput to process large numbers of samples to further refine disease models. The second area to which metabolomics can contribute to improved disease management is improving our understanding of the metabolic mechanisms of disease pathology and how this underlying metabolic phenotype responds to therapeutic intervention. For example, it is unlikely that pharmacological treatment shifts the meta bolic phenotype of diseased state patients back to that of healthy controls, instead, it is much more probable that the phenotype is shifted to a third state that could be considered as the phar macological phenotype [222] [223] [224] . Accordingly, the true power of metabolomics in identifying and quantifying phenotypes will come into play for classifying subphenotypes of disease and their homeo dynamic shifts between disease and pharmacological phenotypes relative to healthy individuals. The acquisition of flux data will enable the development of quantitative models for these dynamic interactions, greatly increas ing our ability to monitor disease and predict patient response to interventions. Metabolites are the end products of cellular processes and can be thought of as the ultimate response of a sys tem to genetics and environment [77] . Studying the metabolite composition of systems using metabol omics approaches will provide a power ful tool in understanding the pathological mech anisms of respiratory diseases and for developing new therapeutic strategies for their treatment.
The next 5-10 years should see some exciting developments in the field of metabolomics. It is expected that the use of metabolomics techniques will become more routine, both in general and in applications to respiratory disease. One of the greatest challenges will remain obtaining compre hensive coverage of the metabolome, especially in determining endogenous from exo genous metab olites, in particular those related to diet or micro biota production. While it is not expected that a single analytical platform will evolve in the near future to address this need, the ability of MS to acquire a greater portion of the metabolome will increase. These efforts will most likely involve multi dimensional chromatography equipped future science group with the ability to analyze several stationary phases in a single ana lysis (e.g., hydrophilic inter action LC, C 18 and ion exchange). These complex multistationary phase instruments in combina tion with extremely high pressures, long analyti cal columns and potentially microfluidics (i.e., nanoflow) will provide the resolution necessary to chromatographically separate a metabolome. These instrument configurations will require highresolution mass spectrometers with very fast scanning rates and the ability to perform mul tiple MS/MS experiments without a significant loss in signal. There will also be a concomitant increased emphasis placed on metabolomics kits (e.g., Biocrates and their MetaDisIDQ ® Kit) and chipbased technologies with, for example, a lipidomicsbased chip designed to capture the lipidome (e.g., Agilent's HPLCChip/MS system). One can envision the production of a respiratory kit or an asthma kit capable of iden tifying or classifying subphenotypes, such as poor glucocorticosteriod responders. One of the major challenges will continue to be the quantitative acquisition of a global metabolome. Given that it is not feasible to have internal standards for all potential metabolites, these efforts will require other novel approaches besides the use of stable isotope dilution or external standards. The field also requires the development of a comprehensive set of analytical standards available as a commer cial kit. Such a product could be used for inter laboratory comparisons to produce quantitative data and for routine quality assurance/quality control. An additional need is for standardized reference material, such as the NIST SRM 1950 plasma. This material consists of a plasma pool collected from an equal number of men and women and with a racial distribution that reflects the US population. The inclusion of this material in each published dataset would provide a stan dardized metric for data normalization. There is a distinct need for a public repository or metabo lomics data along the lines of Gene Expression Omnibus; however, to make these data useful, standardization will be necessary. Accordingly, there are multiple challenges remaining in the widespread application of metabolomics meth ods, but the future is very bright and the field of metabolomics should continue to grow as well as its application to the study of respiratory diseases. 
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Executive summary
Respiratory diseases: the unmet need for new biomarkers & increased understanding of pathobiology
Respiratory diseases are a major cause of global morbidity and mortality.
Metabolomics has yet to be extensively applied to the field of respiratory disease.
Applications of metabolomics methodologies represent an opportunity to gain insight into the pathobiology of respiratory diseases, characterize disease subphenotypes and develop new diagnostic tools.
Choice of clinical material to be analyzed: the importance of matrix selection
Clinical samples have matrix-specific strengths and weaknesses. The appropriate choice depends on the biological question and analytical method being applied. The selection of matrix should be carefully considered during the experimental design phase of any clinical study.
Achievements of metabolomics in the study of respiratory disease: progress in the field to date
Metabolomics approaches can differentiate healthy controls from individuals with a variety of respiratory diseases, including asthma, chronic obstructive pulmonary disorder and cystic fibrosis. These results suggest that there is potential for diagnostic applications.
Metabolomics has implicated numerous metabolites that associate with a range of respiratory diseases, providing insight into potential areas of metabolism responsible for disease pathology.
Challenges in applying metabolomics to the study of respiratory diseases
The most important challenges in a metabolomics experiment include metabolome coverage, data ana lysis, annotation and subsequent interpretation.
The primary clinical challenges for respiratory diseases include rigorous clinical phenotyping of patients, identification of disease-specific subphenotypes and normalization of biofluids (e.g., saliva, sputum, bronchoalveolar lavage fluid and exhaled-breath condensate).
